Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tozinameran

Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein

Phase 2 Most advanced trial
1 Registered trials

What is Tozinameran?

Tozinameran is a lipid nanoparticle-encapsulated, nucleoside-modified messenger RNA encoding an optimized full-length SARS-CoV-2 spike glycoprotein. After injection, the nanoparticles enter nearby cells, where the mRNA is translated into spike protein that may induce antibody and T-cell responses against SARS-CoV-2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BNT 162b2, BNT-162b2, BNT162b2, Comirnaty
Drug type
Vaccine (mRNA vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Pathways
antibody and T-cell mediated immune response
Therapy area
Infectious disease
In trials of
ARCT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5085ZFP6SJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07390968 Phase 2 Hematopoietic and Lymphatic System Neoplasm Not yet recruiting ARCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematopoietic and Lymphatic System Neoplasm

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.